Stryker — May 1, 2025 release

Our updated sales guidance reflects a modestly favorable pricing impact and a slightly unfavorable foreign exchange impact should foreign exchange rates hold near current levels. We expect our adjusted net earnings per diluted share (2) to be the range of $13.20 to $13.45. Our previous guidance on adjusted net earnings per diluted share (2) was $13.45 to $13.70, excluding a dilutive impact of $0.20 to $0.30 from the Inari Medical, Inc. (Inari) acquisition. Our updated guidance reiterates our previous guidance inclusive of dilution from the Inari acquisition while also offsetting a tariff impact of approximately $200 million, which is based on currently available information and our best estimates at this time. (1) A reconciliation of the non-GAAP financial measures: adjusted gross profit margin, adjusted operating income and adjusted operating income margin, adjusted net earnings and adjusted net earnings per diluted share, to the most directly comparable GAAP measures: gross profit margin, operating income and operating income margin, net earnings and net earnings per diluted share, and other important information accompanies this press release. (2) We are unable to present a quantitative reconciliation of our expected net sales growth to expected organic net sales growth as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisitions and divestitures and the impact of foreign currency ex